Nucleic Acid Standards for Biosecurity Act
- Last Action
- 4/29/2025
Actions
- 2026-07-21Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
- 2026-07-20Motion to reconsider laid on the table Agreed to without objection.
- 2026-07-20On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4666)
- 2026-07-20Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4666)
- 2026-07-20DEBATE - The House proceeded with forty minutes of debate on H.R. 3029.
- 2026-07-20Considered under suspension of the rules. (consideration: CR H4666-4667)
- 2026-07-20Mr. Babin moved to suspend the rules and pass the bill, as amended.
- 2026-07-16Placed on the Union Calendar, Calendar No. 654.
- 2026-07-16Reported by the Committee on Science, Space, and Technology. H. Rept. 119-751.
- 2026-07-16Reported by the Committee on Science, Space, and Technology. H. Rept. 119-751.
- 2025-04-29Ordered to be Reported by Voice Vote.
- 2025-04-29Committee Consideration and Mark-up Session Held
- 2025-04-28Referred to the House Committee on Science, Space, and Technology.
- 2025-04-28Introduced in House
- 2025-04-28Introduced in House
CRS Summary
As of 2025-04-28 (00)
Nucleic Acid Standards for Biosecurity Act
This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis.
Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents).
The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.)
In carrying out this effort, NIST must convene stakeholders to develop and periodically update consensus priorities and best practices for synthetic nucleic acid screening mechanisms. Within a specified period, NIST must submit a summary of the stakeholder group’s findings to Congress.
NIST must also take steps to advance risk management best practices and technical standards for engineering biology and biomanufacturing, including with respect to risks associated with the use of artificial intelligence.
Cosponsors (3)
- Richard McCormick (R-GA)
- Sarah McBride (D-DE)
- Josh Riley (D-NY)
Subjects
- Biological and life sciences
- Cell biology and embryology
- Research and development
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.